DENTSPLY SIRONA Inc. (XRAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

37.65

+0.48

(+1.29%)

At close: 04:00PM EDT

37.65

0.00

(0.00%)

After hours:

04:49PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	37.17
Open	37.24
Bid	37.50 x 2200
Ask	37.87 x 1800
Day's Range	37.18 - 37.67
52 Week Range	33.78 - 63.10
Volume	845,700
Avg. Volume	1,894,325

Market Cap	8.112B
Beta (5Y Monthly)	0.92
PE Ratio (TTM)	22.28
EPS (TTM)	1.69
Earnings Date	Aug 15, 2022 - Aug 19, 2022
Forward Dividend & Yield	0.50 (1.35%)
Ex-Dividend Date	Sep 29, 2022
1y Target Est	42.70

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-19% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for XRAY

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

DENTSPLY SIRONA Inc.
XRAY: What does Argus have to say about XRAY?DENTSPLY SIRONA INC has an Investment Rating of HOLD; a target price of $38.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
Rating
Fair Value
Economic Moat
last monthArgus Research

All

American City Business Journals
Dentsply Sirona exec leaving as internal probe of financial irregularities expands
Dentsply Sirona says its internal investigation into financial-reporting irregularities has expanded. The company warns that preliminary quarterly results released in May will have to be corrected and that 2021 financials may have to be restated.
Zacks
DENTSPLY SIRONA (XRAY) Up on Strong Q2 Preliminary Results
DENTSPLY SIRONA's (XRAY) preliminary second-quarter 2022 results reflect the normalizing business, aided by product launches and pricing adjustments. Shares rise.
- Why These 10 Stocks are Skyrocketing on Friday
  Insider Monkey
- Consolidated Water (CWCO) Q2 Earnings & Sales Beat Estimates
  Zacks
Benzinga
Dentsply Sirona Expects Q2 Sales of Over $1B, To Miss Quarterly Filing Deadline
Dentsply Sirona Inc (NASDAQ: XRAY) expects to report Q2 FY22 net sales of over $1.01 billion. Additionally, diluted EPS is expected to be at or above $0.26 and adjusted EPS at or above $0.60. The company said that though sales declined Y/Y due to the unfavorable impact of foreign exchange, the business delivered organic sales growth driven by solid European regional performance and demand in CAD/CAM, Equipment & Instruments, and Restorative and Preventive Consumables. The company continued to ex